Exact Sciences Corporation
EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Testā¦ read more
Healthcare
Diagnostics & Research
25 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$103.57
Price+0.29%
$0.30
1Y
Price
Market Cap
$19.770b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-2.3%
EBITDA Margin-9.8%
Net Profit Margin+13.7%
Free Cash Flow Margin-2.3%
EBITDA Margin-9.8%
Net Profit Margin+13.7%
Free Cash Flow MarginRevenue
$3.247b
+17.7%
1y CAGR+16.0%
3y CAGR+16.5%
5y CAGREarnings
-$207.949m
+79.8%
1y CAGR-85.6%
3y CAGR-65.4%
5y CAGREPS
-$1.10
+80.3%
1y CAGR-82.1%
3y CAGR-62.0%
5y CAGRBook Value
$2.401b
$5.861b
Assets$3.460b
Liabilities$2.523b
DebtDebt to Assets
43.0%
59.2x
Debt to EBITDAFree Cash Flow
$356.782m
+378.6%
1y CAGR+206.5%
3y CAGR+133.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company